New York, May 20, 2026, 18:04 (EDT)
- BioVie closed at $1.35, up 3.05%, after a choppy three-session run tied to its Parkinson’s trial update.
- The company said the last patient evaluation visit was completed in its SUNRISE-PD Phase 2 trial.
- Investors now face a Q3 readout, with cash needs and trial risk still central.
BioVie Inc. shares rose on Wednesday after the clinical-stage drug developer said its SUNRISE-PD Parkinson’s trial had completed the last patient evaluation visit, moving the story from enrollment and dosing toward data. The stock closed at $1.35, up 3.05%, after trading between $1.31 and $1.37.
That matters now because BioVie is a small, low-volume biotech whose valuation is tied closely to clinical events. At Wednesday’s close, the company had a market value of about $10.2 million, and trading volume was 19,735 shares, below the 89,680 average shown by Google Finance.
The next marker is Q3. BioVie said it is targeting topline data — the first summary of whether key trial measures were met — in the third quarter of 2026 for bezisterim, its experimental oral drug for early-stage Parkinson’s disease.
The shares have not traded in a straight line. BIVI gained 3.82% on Monday, fell 3.68% on Tuesday and rose 3.05% on Wednesday, leaving the stock almost flat since the trial-completion announcement.
BioVie President and CEO Cuong Do said the company would start the study closeout process and “unblind the data later this year.” Unblinding means researchers learn which patients received the drug and which received placebo after the study data are locked. BioVie Inc.
SUNRISE-PD is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled trial in early-stage Parkinson’s patients who had not been treated with carbidopa/levodopa. Double-blind means neither patients nor treating staff know who received the drug or placebo during the trial; placebo-controlled means the drug is compared with an inactive treatment.
During the 12-week double-blind phase, 57 patients were randomized 1:1 to receive either 20 mg of bezisterim or placebo twice daily, the company said. BioVie said the trial looked at motor and non-motor endpoints, including movement scores, sleep, quality-of-life measures and biomarkers linked to inflammation and neurodegeneration.
The broader tape helped. The Nasdaq was up 1.55% on Wednesday, while the SPDR S&P Biotech ETF rose about 3.9% and the iShares Nasdaq Biotechnology ETF gained about 2.2%, giving small biotech shares a firmer backdrop.
Competitive pressure is different from a straight drug-versus-drug fight. BioVie is testing a potential early-stage Parkinson’s therapy aimed at motor and non-motor symptoms, while approved products from companies such as AbbVie and Supernus focus on advanced Parkinson’s “off” episodes, periods when symptoms return as medication wears off. Reuters
But the downside case is plain. A 57-patient Phase 2 study may not produce results strong enough to support Phase 3 plans, and even positive data would still require larger trials, financing and regulatory review. BioVie’s latest quarterly filing said it had $13.1 million in cash and cash equivalents at March 31, was pre-revenue, and that its need to raise capital raised substantial doubt about its ability to continue as a going concern.
For now, BIVI is a data-readout trade. The stock has bounced, but the close-to-close move since Monday shows investors have not yet treated the trial milestone as proof of a drug.
